Adam M. Sonabend

This study shows that preoperative temozolomide exposure in recurrent glioblastoma leads to inflammatory-repair remodeling and a ROCK-linked therapeutic vulnerability, which can be targeted by fasudil.

This study shows that ultrasound-mediated BBB modulation alone does not generate effective CNS immunity, but combining it with systemic immune activation enhances T-cell responses and improves immunotherapy efficacy.

The paper develops RNA nanotherapeutics targeting TAMC cholesterol metabolism to enhance anti-tumor immunity in glioblastoma.

This study identifies the MAPK/ERK pathway as a key regulator of glioma susceptibility to immune checkpoint blockade, showing it modulates interferon responses, T cell recruitment, and tumor-microglia interactions.

This study identifies THOC1 as a driver of glioblastoma progression by interacting with SIN3A to regulate R-loops and telomere stability.

This study shows targeting ZNF638 induces viral mimicry and enhances immune checkpoint inhibition in glioblastoma by increasing dsRNA signaling and PD-L1 expression.

This study identifies the CHK2-YBX1&YBX3 hub as an immunosuppressive mechanism in gliomas and shows that targeting it with SU056 enhances immune checkpoint blockade efficacy.

The paper introduces metaVIPER, an algorithm to assess protein activity in orphan tissues and single cells by integrating multiple non-tissue-matched interactomes, improving reproducibility of protein-activity signatures.